Drug-coated balloon versus drug-eluting stent for treating de novo proximal left anterior descending artery lesions: Insights from the REC-CAGEFREE I trial - PubMed
6 hours ago
- #Percutaneous coronary intervention
- #Drug-coated balloon
- #Drug-eluting stent
- The study compares drug-coated balloon (DCB) and drug-eluting stent (DES) for treating proximal left anterior descending (LAD) artery lesions.
- DCB treatment showed a higher risk of 2-year device-oriented composite endpoint (DoCE) compared to DES in proximal LAD lesions (8.8% vs. 3.4%).
- Similar higher risk of DoCE was observed with DCB in non-proximal LAD lesions (5.4% vs. 3.3%).
- No significant interaction was found between lesion location and treatment strategy (DES/DCB).
- Proximal LAD lesions treated with DCB had a higher risk of DoCE compared to non-proximal LAD lesions (8.8% vs. 5.4%).
- The study concludes DCB is associated with a higher 2-year risk of DoCE than DES across all lesion locations, with a numerically larger effect in proximal LAD.
- Results should be interpreted cautiously due to the exploratory nature of the analysis.